BELLUS Health Receives Nasdaq Deficiency Notice Relating to Market Value



    LAVAL, QC, Oct. 15 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ:   BLUS;
TSX: BLU) announces that it received a Nasdaq Staff Deficiency Letter dated
October 10, 2008, stating that, for 10 consecutive trading days, the market
value of the Company's listed securities has been below the minimum
$50 million requirement for continued inclusion on The Nasdaq's Global Market
under Marketplace Rule 4450(b)(1)(A). The Company believes that the recent
decline in its market value is due to the general pressure on equity markets
worldwide.
    In accordance with Marketplace Rule 4450(e)(4), the Company has
30 calendar days, or until November 10, 2008, to regain compliance to which
BELLUS Health will strive towards. If the market value of the Company's common
stock is US$50,000,000 or more for a minimum of 10 consecutive business days
at any time prior to November 10, 2008, Nasdaq may determine that the Company
has regained compliance with the applicable listing requirements. If
compliance with the Rules cannot be demonstrated by November 10, 2008, Nasdaq
will provide written notification that the Company's securities will be
delisted, at which time the Company may appeal the determination to a Listing
Qualifications Panel.
    Among other alternatives the Company is considering if it cannot regain
compliance with the requirements of The Nasdaq's Global Market as set forth
above, is applying to transfer its securities to The Nasdaq Capital Market.
Currently, the Company believes that it meets the criteria to transfer to The
Nasdaq Capital Market. However, there can be no assurance that Nasdaq will
approve the Company's transfer application.
    The Company's common stock is also listed on the Toronto Stock Exchange
(TSX) and such listing is not affected by the notice received from Nasdaq.

    About BELLUS Health

    BELLUS Health is a global health company focused on the development and
commercialization of products to provide innovative health solutions to
address critical unmet medical needs.

    To Contact BELLUS Health

    For additional information on BELLUS Health and its drug development
programs, please call the Canada and United States toll-free number
1-877-680-4500 or visit the Web Site at www.bellushealth.com.

    Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond BELLUS Health
Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are
not limited to: the impact of general economic conditions, general conditions
in the pharmaceutical and/or nutraceutical industry, changes in the regulatory
environment in the jurisdictions in which the BELLUS Health Group does
business, stock market volatility, fluctuations in costs, and changes to the
competitive environment due to consolidation, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, as well as other risks disclosed in public filings of BELLUS
Health Inc. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on any forward-looking statements
included in this news release. These statements speak only as of the date made
and BELLUS Health Inc. is under no obligation and disavows any intention to
update or revise such statements as a result of any event, circumstances or
otherwise, unless required by applicable legislation or regulation. Please see
the Annual Information Form of BELLUS Health Inc. for further risk factors
that might affect the BELLUS Health Group and its business.




For further information:

For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4572, lhebert@bellushealth.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890